GSK (MEX:GSKN) Research & Development: MXN190,906 Mil (TTM As of Mar. 2026)


MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN901.11
GF Value MXN818.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GSK Research & Development?

GSK MEX:GSKN 73 Research & Development is MXN190,906 Mil as of Mar. 2026. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GSK's Research & Development for the three months ended in Mar. 2026 was MXN40,682 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN190,906 Mil.

GSK  (MEX:GSKN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GSK Research & Development Related Terms

GSK Research & Development Historical Data

* Premium members only.

The historical data trend for GSK's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Research & Development Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136,914.58 130,321.62 133,709.80 168,770.34 181,382.72

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38,643.27 51,710.04 41,869.40 56,644.44 40,681.77
MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN190,906 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN190,906 Mil mean?
GSK (MEX:GSKN) has a Research & Development of MXN190,906 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on GSK and its competitors.
Is GSK's Research & Development too high?
GSK's current Research & Development is MXN190,906 Mil. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Research & Development compare to LLY and JNJ?
GSK's Research & Development of MXN190,906 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GSK and its competitors. GSK's current Research & Development is MXN190,906 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Research & Development is MXN190,906 Mil. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Research & Development is MXN190,906 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82. GuruFocus considers GSK to be Fairly Valued.

Key valuation signals for MEX:GSKN:

  • Research & Development: MXN190,906 Mil
  • GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN901.11
Price
MXN818.82
GF Value